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Abstract
Background: NF2 is an autosomal dominant disease characterized by development of bilateral vestibular schwannomas and
other benign tumors in central nervous system. Loss of the NF2 gene product, Merlin, leads to aberrant Schwann cell
proliferation, motility, and survival, but the mechanisms by which this tumor suppressor functions remain unclear. One well-
defined target of Merlin is the group I family of p21-activated kinases, which are allosterically inhibited by Merlin and which,
when activated, stimulate cell cycle progression, motility, and increased survival. Here, we examine the effect of Pak
inhibition on cells with diminished Merlin function.
Methodology/Principal Findings: Using a specific peptide inhibitor of group I Paks, we show that loss of Pak activity
restores normal cell movement in cells lacking Merlin function. In addition, xenografts of such cells form fewer and smaller
tumors than do cells without Pak inhibition. However, in tumors, loss of Pak activity does not reduce Erk or Akt activity, two
signaling proteins that are thought to mediate Pak function in growth factor pathways.
Conclusions/Significance: These results suggest that Pak functions in novel signaling pathways in NF2, and may serve as a
useful therapeutic target in this disease.
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Introduction
Neurofibromatosis type 2 (NF2) is an autosomal dominant
disorder characterized by the development of bilateral vestibular
schwannomas and other benign tumors in central nervous system
[1,2]. While several mitogenic pathways are known to be
upregulated in NF2-mutant cells, despite considerable effort, there
is as yet no consensus as to how loss of the NF2 tumor suppressor
gene leads to schwannoma growth, nor are there effective medical
therapies for this disorder.
The protein encoded by the NF2 gene, Merlin, exhibits
significant homology to Ezrin-Radixin-Moesin (ERM) proteins,
sharing a FERM (Four-point one, Ezrin, Radixin, and Moesin)
domain at the N-terminus followed by an alpha-helical segment.
Merlin has a unique C-terminal domain lacking a binding region
for F-actin that exists in all other ERM proteins [3]. Within the
FERM domain, a seven amino-acid conserved sequence (termed
the ‘‘Blue Box’’), is important for Merlin functions. In Drosophila,
deletion of this sequence (DBB) or substitution of polyalanine
within this region (BBA) results in a dominant-negative form of the
protein [4], most likely by disrupting intramolecular association
between the N- and C-termini of Merlin [5]. This self-interaction
can also be disrupted by phosphorylation of Merlin at residue
serine 518, leading to a functionally inactive ‘‘open state’’ [6].
Merlin phosphorylation at this site is stimulated by Rac1 and
Cdc42 GTPases via activation of their downstream effectors, p21-
activated kinases (Paks) [7,8].
Merlin is known to play an inhibitory role in Rac-mediated
signaling [6]. NF2-deficient Schwannoma cells display aberrant
membrane ruffling and concomitant hyperactivation of Rac and
Pak1 [9,10,11]. Fibroblasts and keratinocytes lacking Merlin lose
contact inhibition and Nf2-null neuroendocrine cells are defective
in assembly of tight junctions and adherens junctions [12],
processes disrupted by activated Rac and Pak [13,14,15]. Merlin
affects Rac trafficking to the plasma membrane and is a direct
inhibitor of Pak1, suggesting a negative feed-forward loop between
Rac/Pak and Merlin [16]. For these reasons, The Rac/Pak
signaling axis has garnered increasing attention as a possible
therapeutic target in NF2.
As downstream mediators of Rac function, Paks have been
implicated in regulating cell morphology, motility proliferation,
and survival [17,18,19]. Group I Paks (Pak1, -2, and -3) affect a
wide variety of central signaling pathways, including positively
regulating mitogen activated kinases (MAPKs), Akt, and NFkB
[20,21]. In addition, group I Paks influence the G2/M transition
by activating Aurora-A and Polo-like kinase 1 (Plk-1) [22,23]. In
Ras-transformed cells, expression of dominant- negative Pak1
blocks transformation and prevents full activation of Erk and Jnk,
and it is thought such MAPKs represent important signaling
targets for Pak in cancer [24,25]. In the Erk pathway, Pak has
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13791been shown to phosphorylate c-Raf at S338 and Mek1 at S298
[26,27,28,29]. These phosphorylations are thought to be neces-
sary, but not sufficient, for full activation of c-Raf and Mek by Ras.
In this study, we show that inhibition of group I Paks in Nf2-
mutant fibroblasts reduces proliferation, restores normal morphol-
ogy, and reduces invasiveness of cells lacking Merlin function, as
well as the tumorigenicity of such cells in nude mice. However,
these changes are not associated with reductions in Erk or Akt
activity; in fact, the activity of these pathways is augmented,
suggesting that the beneficial effects of inhibiting Pak in these cells
involves novel signal transduction pathways.
Results
Establishing Merlin-deficient cells that express a Pak
inhibitor
To study the influence of Pak inhibition in cells lacking Merlin
function, we established a stable NIH-3T3 fibroblast cell line
overexpressing Merlin DBB, a mutant form of the tumor
suppressor that lacks the ‘‘Blue Box’’ motif and which, in
Drosophila, acts in a dominant negative fashion, in effect mimicking
loss of the NF2 gene (Fig. 1A) [30]. Another ‘‘Blue Box’’ mutant,
Merlin BBA, has been shown to be tumorigenic in mammals
[31,32], though Merlin DBB and Merlin BBA are reported to
show some differences with respect to effects on cell shape and
adhesiveness [30,31]. The expression level of Merlin DBB in such
infected cells was about 5-fold higher than endogenous Merlin
(Fig. 1B and Fig. S1). Note that, despite deletion of the Blue Box
motif, exogenous Merlin DBB migrates at the same position as
endogenous Merlin in SDS/PAGE. NIH-3T3 cells expressing
dominant negative Merlin (DBB cells) were then infected with
recombinant retrovirus encoding GST-tagged Pak inhibitor
domain (PID) or a nonfunctional inhibitor control, PID L107F
(PID LF) [27]. The DBB cells infected with the PID or PID LF
retrovirus displayed readily detectable signals in anti-GST
immunoblots (Fig. 1B).
Figure 1. Establishment of cells with loss of Merlin and/or Pak function. (A) Schematic of experimental design. NIH-3T3 cells were infected
with a control retrovirus or a retrovirus encoding dominant negative Merlin (Merlin DBB). These cells were then infected with a retrovirus encoding
the Pak inhibitor (PID) or an inactive control (PID LF). (B) Cells were starved overnight and then stimulated with PDGF for 5 min. Immunoblots for
Merlin, (GST)-PID, and actin are shown.
doi:10.1371/journal.pone.0013791.g001
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expressing dominant negative Merlin
We first examined the effect of Merlin on cell morphology and
invasiveness and asked if such effects could be reversed by PID
expression. Cells expressing DBB became fusiform as compared to
normal NIH-3T3 cells (Fig. 2A). Expression of the PID, but not
the control PID LF, showed substantial restoration of normal
morphology. For invasion studies, cells were plated in a chamber
above a layer of Matrigel and assessed for their ability to penetrate
through this layer, indicating invasiveness. As shown in Fig. 2B
and Table S1, the invasiveness of DBB cells was almost twice that
of control NIH-3T3 cells. Assuming linear invasion kinetics,
expression of PID, but not PID LF, significantly inhibited the
invasive capacity of Merlin DBB cells. Thus, a Pak inhibitor
substantially reduced invasiveness in cells expressing a dominant-
negative form of Merlin. In control NIH-3T3 cells, PID expression
had a slight effect on morphology, and reduced invasiveness by
about 10% (Fig. 3 and Table S2).
Inhibition of tumor formation by Pak inhibition
To assess the effects of Pak inhibition on NF2-related
tumorigenicity, we injected nude mice only with DBB, DBB/
PID, or DBB/PID LF cells. DBB cells developed substantial
tumors by 6 weeks post-injection (average volume .200 mm
3),
similar to previous studies in which the Merlin BBA mutant was
used [31,32]. Tumors derived from DBB/PID cells were much
smaller in size, with an average volume of 38 mm
3 (Fig. 4).
Interestingly, mice injected with DBB/PID LF cells developed
tumors even larger (average volume ,450 mm
3) than those
injected with DBB cells. Similar experiments were also carried out
in NIH-3T3 cells lacking the DBB transgene (Fig. 5). In this latter
case, only very small tumors were noted after 6 weeks (compare
Fig. 4 with Fig. 5), but, as with the DBB xenograft, these masses
were larger in cells expressing PID LF (Fig. 5).
Lastly, we examined signaling activity in tumor lysates from
these xenografts. Pak activity was inhibited in DBB/PID cells,
indicating that this suppressor remained effective in vivo.
Figure 2. Effects of PID on morphology and invasion. (A) Cells expressing Merlin DBB, Merlin DBB/PID, or Merlin DBB/PID LF were fixed and
stained for F-actin (red) and for DNA (blue). (B) The invasiveness of control cells or cells expressing Merlin DBB, Merlin DBB/PID, or Merlin DBB/PID LF
was determined over 12 hr by Matrigel invasion chamber assay as compared against uninfected control cells. The experiments were performed three
times with similar results. The data are presented as the means 6 S.D. of duplicate well measurements from one representative experiment. (C)
Staining pattern of cells that have migrated and adhered to the bottom surfaces of filters in cell invasion assay. The small circles are cross-sectionso f
8 mm pores. Scale bar =50 mm.
doi:10.1371/journal.pone.0013791.g002
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from animals injected with DBB or DBB/PID LF cells, both Akt
and Erk were activated in lysates from the small tumors that
developed in mice injected with DBB/PID (Fig. 6). It is also of
interest that, in the tumors from DBB/PID mice, Merlin
expression (presumably exogenous Merlin DBB) was substantially
elevated. These data show that PID expression strongly inhibited
tumor formation in the NF2 xenograft model, suggesting that
Group I Paks are required for transformation in cells that have lost
Merlin function. Despite this requirement, loss of Pak function did
not reduce Akt or Erk activity; on the contrary, it activated them.
In the small tumors observed in NIH-3T3 xenografts, the effects of
the PID on signaling were consistent with prior literature: PID
expression decreased Pak activity, as well as the Mek phosphor-
ylation at S298, Mek activity, and ERK activity (Fig. 7). In these
small tumors, Merlin expression was not affected in a consistent
way, nor was activation of Akt altered.
Discussion
In this report, we have shown that the effects of a dominant
acting Merlin protein can be largely reversed by inhibition of
group I Paks. As has been noted previously, expression of a
different ‘‘Blue Box’’ mutant of Merlin alters the actin cytoskel-
eton, promotes invasiveness, and confers the ability to form tumors
in nude mice [31]. Given that Pak is activated in cells lacking
functional Merlin [32] and that some of these aberrant phenotypes
resemble those shown in cells with hyperactivation of Pak1,
blockade of Pak might represent a reasonable therapeutic strategy
in NF2.
Figure 3. Effect of Pak inhibition on morphology and invasiveness in NIH-3T3 cells. Control NIH-3T3 cells and NIH-3T3 cells stably
expressing PID or PID LF were starved for 24 hrs in serum-free medium, then stimulated for 5 min with 5 ng/ml; PDGF. (A) Protein lysates were
separated by SDS-PAGE, blotted, and probed with the indicated antibodies. (B) Cells expressing Merlin DBB, Merlin DBB/PID, or Merlin DBB/PID LF
were fixed and stained for F-actin (red) and for DNA (blue). (C) The invasiveness of control cells or cells expressing Merlin DBB, Merlin DBB/PID, or
Merlin DBB/PID LF was determined over 24 hr by Matrigel invasion chamber assay as compared against uninfected control cells. The experiments
were performed three times with similar results. The data are presented as the means 6 S.D. of duplicate well measurements from one representative
experiment. (D) Staining pattern of cells that have migrated and adhered to the bottom surfaces of filters in cell invasion assay. The small circles are
cross-sections of 8 mm pores. Scale bar =50 mm.
doi:10.1371/journal.pone.0013791.g003
Role of Pak in NF2
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13791The involvement of Akt and Erk in NF2 pathobiology is
controversial. Some studies report elevated Akt and Erk in NF2-
deficient cells [33,34,35,36], whereas others report no correlation
[37,38]. Our results are consistent with these latter studies, in that
cells lacking Merlin, whether grown in vitro or when recovered from
xenografttumors, displayed low basal Akt and Erkactivity. Curiously,
in the few small tumors that developed from DBB/PID xenografts,
Akt and Erk activities were elevated (Fig. 6). The same was true for
DBB/PID cellsgrown in vitro (data not shown). These activations may
reflect an altered signaling strategy in the tumor cells, necessary to
overcome loss of Pak activity due to PID expression.
Our studies also show that the DBB mutant of NF2, like another
commonly studied ‘‘Blue Box’’ mutant, Merlin BBA, is in fact
tumorigenic in mice. Whether this mutant acts in precisely the
same manner as the better-studied BBA mutant is unclear, as these
two mutants are reported to have different effects on cell
adhesiveness and morphology. Despite these issues, it is clear that
the DBB mutant has major effects on mouse cell morphology,
invasiveness, and tumorigenicity, and that these changes are not
accompanied by marked upregulation of Erk or Akt.
The data reported here are in general agreement with a
previous study conducted by Yi et al., in which Pak inhibition by
shRNAs reduced tumor volume of dominant-negative NF2-
expressing cells [32], but also have some intriguing differences.
Interestingly, in the study by Yi et al., escape from Pak knock-down
occurred when expression of the Pak1 shRNA hairpin was silenced
by methylation of the H1 promoter in the NF2 tumor cells. In our
studies, which employed a peptide inhibitor of Pak rather than
shRNA, we noted that the few, small tumors that arose in animals
injected with DBB/PID cells did not shut off the PID transgene
but did show significant increases in Merlin expression (Fig. 5).
Because endogenous Merlin and the DBB Merlin mutant have
similar mobility on SDS/PAGE, it was not possible to determine if
the increased expression is due to endogenous or exogenous (DBB)
Merlin, but we favor the idea that it represents DBB Merlin,
especially in light of the lack of consistent increase in endogenous
Merlin levels in xenograft tissues from cells expressing PID alone
(Fig. 7). Therefore, we believe that the most likely explanation for
these findings is that increased Merlin DBB expression was
required for the tumor cells to escape inhibition consequent to
diminished Pak function. Thus, both the results of our study and
that of Yi et al. suggest that Pak activity is required for efficient
tumorigenesis in cells that have lost Merlin function. In addition,
our study shows that down-regulating Pak expression per se is not
Figure 4. Effects of PID on tumor formation. Tumor formation was assessed by subcutaneously inoculating 1610
6 NIH-3T3 cells infected with
empty vector (Vector) into left flanks and equal number of Merlin-expressing cells (DBB, DBB/PID and DBB/PID LF, respectively) into right flank of the
same mice. Five mice were used for each cell line. Tumor diameters were measured every 3 days using caliper for 6 weeks following injection. (A)
Representative photographs of nude mice with solid tumors (left panel). Enlarged images of boxed area in the left panel (right panel). (B, C) Tumor
volume was calculated by the formula described in Material and Methods. Horizontal lines represent the average tumor diameter.
doi:10.1371/journal.pone.0013791.g004
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activity of endogenous Pak is sufficient for these beneficial effects.
A number of peptide based reagents, such as PID and cell-
penetrating peptides based on the Nck or PIX binding regions of
Pak, have been used to effectively block Pak function in cells and
in vivo [39,40]. One note of caution raised by our studies is that
the putative negative control for the PID, PID LF, appears to
have gain-of-function effects in a variety of cell types. The PID
LF mutant has been thought to represent a functionless, inert
control for the PID, incapable of inhibiting Pak or binding to its
partners such as the Fragile X protein [41]. Our results here
should inject a note of caution in the use of this construct.
Instead, one may consider small molecule inhibitors of Pak.
Recently, a few specific small molecule inhibitors of group I Paks
have also been described, including OSU03012, lambdaFL172
[42], and IPA-3 [43]. The latter of these three compounds has
been shown to inhibit membrane ruffling and cell spreading in
NF2
2/2 schwannoma cells [44]. Interestingly, in these experi-
ments, blockade of Pak with IPA-3 reduced Rac activity,
suggesting that Pak acts upstream of Rac in these cells. Though
Rac also activates Pak, such an idea is consistent with models
which link Pak to further Rac activation via the Pak-bound
guanine-nucleotide exchange factor, PIX [37,45]. These results,
like ours, support the notion that the Rac/Pak signaling axis is
activated as a consequence of Merlin loss, and that these enzymes
might provide useful targets for therapy in NF2.
Materials and Methods
Cell culture conditions and retroviral transductions
NIH-3T3 (obtained from American Type Culture Collection)
cells were cultured in high-glucose DMEM supplemented with
10% fetal calf serum, 2 mM L-glutamine and 100 U/ml
penicillin/streptomycin at 37uC in a humidified 5% CO2
incubator. The wNX packaging cell line (Orbigen) was transfected
using Lipofectamine 2000 (Invitrogen). Viral supernatants were
harvested 48 hr post-transfection and filtered. Cells were incubat-
ed with retroviral supernatant supplemented with 4 mg/ml
polybrene for 4 hr at 37uC, and then were cultured in growth
media for 48 hr for viral integration. Infected cells were selected
with 2 mg/ml of puromycin or by flow cytometry for cells with
green fluorescent protein (GFP).
Figure 5. Effects of PID on tumor formation. Tumor formation was assessed by subcutaneously inoculating 1610
6 NIH-3T3 cells infected with
empty vector (Vector) into left flanks and equal number of NIH-3T3 cells expressing PID or PID LF, respectively) into right flank of the same mice. Five
mice were used for each cell line. Tumor diameters were measured every 3 days using caliper for 6 weeks following injection. (A) Representative
photographs of nude mice with solid tumors (left panel). Enlarged images of boxed area in the left panel (right panel). (B, C) Tumor volume was
calculated by the formula described in Material and Methods. Horizontal lines represent the average tumor diameter.
doi:10.1371/journal.pone.0013791.g005
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A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F
cDNA [27] was subcloned as a BglII/XhoI fragment into the
retroviral expression vector pBMN-I-GFP (http://stanford.edu/




4 cells were plated in 96-well plates and 10 ml 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
solution was added to each well to a final concentration of
0.5 mg/ml. The reaction was stopped after 4 hr at 37uCb y
adding 100 ml of solubilization solution (10% SDS in 0.01 M HCl)
and the samples were analyzed at 595 nm on Perkin Elmer
Envision plate reader. Triplicates were performed for each sample
and medium alone was used as a blank, and experiments were
performed on three occasions.
Cell invasion assay
Matrigel invasion chamber (BD Biosciences) were rehydrated in
serum-free DMEM medium for 2 hr and then placed in 0.75 ml of
DMEM medium supplemented with 5% fetal calf serum. Cells at a
density of 1.5610
4 suspended in 0.5 ml of DMEM, and seeded
onto Matrigel chambers. Cells were allowed to invade for 12 or
24 hr and cells on the upper surface were gently removed with a
cotton bud, and cells that had migrated through the 8 mm pores
were fixed with 4% paraformaldehyde for 15 min and stained with
0.1% crystal violet for 15 min. Membranes were washed, removed
and mounted on a glass slide, and the level of invasion was
quantified by visual counting using a microscope with a 20X
objective.
Cell cycle analysis
Cell cycle profiles were analyzed using flow cytometry with
propidium iodide staining. Cells were trypsinized and washed with
PBS and fixed in 70% ethanol at 220uC. After fixation, cells were
washed once with PBS and resuspended in 0.5 ml of a solution
containing 1 M Tris-HCl pH 8.0, 0.1% Nonidet P-40, 10 mM
NaCl, 50 mg/ml propidium iodide and 70 Kunitz units/ml RNase
A. FACS analysis was performed using CELLQuest
TM software
(Becton Dickinson). A minimum of 10,000 events was collected per
sample.
Immunoblot analysis
Whole cell extracts were prepared by washing the cells in cold
PBS and lysed in a buffer containing 50 mM Tris-HCl pH 7.5,
150 mM NaCl, 1% Nonidet P-40, and 0.25% sodium deoxycho-
late, 1 mM Na3VO4, and 1 mM NaF, plus complete protease
inhibitor cocktail tablets (Roche). Protein concentrations were
determined using bicinchoninic protein assay reagent according to
manufacture’s instructions (Pierce). Pak activation was stimulated
by adding PDGF-BB (Sigma) at 5 ng/ml for 5 min to serum-
starved cells. The antibodies used in this study include Pak1; Pak2;
Mek1/2; phospho-MEK1 (Ser298); Erk1/2; phospho-Erk1/2
(Thr202/Tyr204); Akt; phospho-Akt (Thr308); Merlin (Cell
Signaling Technology); phospho-Pak1–3 (Ser141; Invitrogen);
GST (Santa Cruz Biotechnology); and b-actin (Sigma). All
antibodies were used at a dilution of 1:1,000, except for b-actin,
which were diluted in 1:20,000.
Immunofluorescence
Cells were plated on glass coverslips in 6-well culture plates and
fixed in 4% paraformaldehyde for 10 min, permeabilized with
0.2% Triton X-100 for 5 min and blocked with 1% BSA in PBS
for 30 min. Filamentous actin and nuclei were visualized by
staining with Rhodamine-phalloidin (Molecular Probe) and DAPI
(Sigma), respectively. Images were observed and captured on an
inverted phase/fluorescence microscope (Nikon TE300).
Tumorigenicity assays
Cells were trypsinized, washed with PBS and resuspended at
10
7 cells per ml in PBS. 2610
6 cells were injected subcutaneously
into flanks of 5-week old nude mice (BALB/c nu/nu). Mice were
monitored and tumor diameters were measured every 3 days using
caliper for 6 weeks following injection. Tumor volume was
calculated by the following formula: volume =0.56 (length) 6
(width)
2. The mice were sacrificed and the tumors were resected
for histological examination and immunoblot analysis. All animals
Figure 6. Activity of signaling pathways in tumor samples from
xenografts. Tumor from six mice were resected and immediately lysed
in a buffer containing 10 mM PBS pH 7.2, 1% Triton X-100, 0.1% SDS,
20% glycerol, plus complete protease and phosphatase inhibitor tablets
(Roche). Lysates were separated by SDS-PAGE and incubated with the
indicated antibodies.
doi:10.1371/journal.pone.0013791.g006
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defined by the relevant national and/or local animal welfare
bodies, and all animal work was approved by the FCCC IACUC
committee (Protocol 96-10), active 08/09 - 08/10.
Data analysis
All experiments were performed at least three times. Results are
reported as means 6 SD. The significance of the data was
determined by two-tailed, unpaired Student’s t-test, and differ-
ences were considered statistically significant at P,0.05.
Supporting Information
Figure S1 Delta BB Merlin expression in NIH-3T3 cells.
Expression of Merlin from the experiment shown in Fig. 1B was
quantitated using NIH Image J software.
Found at: doi:10.1371/journal.pone.0013791.s001 (0.04 MB PDF)
Table S1 Raw cell invasion data for Fig. 2. Cell invasion studies
were performed as described in Materials and Methods and in the
legend to Fig. 2. Control insert = invasion in absence of Matrigel
plug.
Found at: doi:10.1371/journal.pone.0013791.s002 (0.05 MB
DOC)
Table S2 Raw cell invasion data for Fig. S1. Cell invasion
studies were performed as described in Materials and Methods
and in the legend to Fig. 2. Control insert = invasion in absence
of Matrigel plug.
Found at: doi:10.1371/journal.pone.0013791.s003 (0.06 MB
DOC)
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